Exosens Reports Impressive Growth and Profitability for H1 2024
H1 2024 RESULTS
MÉRIGNAC, FRANCE – Exosens, a prominent high-tech firm specializing in critical amplification, detection, and imaging technologies, has announced remarkable results for the first half of the year ending June 30, 2024.
Key Highlights:
- Revenue Growth: The company achieved a significant revenue increase of 50%, amounting to €186.9 million. This surge was driven by a 35% organic growth on a like-for-like basis, along with strategic acquisitions.
- Improved Profitability: The adjusted gross margin reached €91.1 million, which is 48.8% of revenue, marking an increase of 350 basis points compared to H1 2023.
- EBITDA Performance: Adjusted EBITDA rose to €56.1 million, resulting in an EBITDA margin of 30%, up from 27.2% in H1 2023.
- Strong Financial Health: As of June 30, 2024, net leverage was at 1.3x following the successful IPO.
“The first half of the year has been transformative for Exosens. The €180 million capital increase from our IPO, combined with solid revenue growth, showcases our successful operational strategies and recent acquisitions. Our profitability trajectory further confirms the strength of our business model. We are ready to capitalize on future opportunities while keeping our focus on innovation and sustainable growth,” stated Jérôme Cerisier, CEO of Exosens.
Ongoing Growth Momentum with Significant Revenue Increases
Exosens has shown exceptional growth, with consolidated revenues for H1 2024 reaching €186.9 million. This 50% increase is largely due to substantial organic growth, improved group sales volume, and a favorable product mix. The integration of Telops, El-Mul, and ProxiVision, which were acquired in recent months, has played a crucial role in this growth. The collaborative efforts of the sales and R&D teams have facilitated a smooth integration of technologies.
Specifically, Amplification revenue climbed to €138.5 million, reflecting a 46.8% increase due to a favorable product mix. On the other hand, Detection & Imaging revenue reached €50.4 million, showing a robust increase of 60.2%, driven by advantageous pricing, effective cost control, and the successful consolidation of acquired entities.
Key Financial Highlights
The detailed financial results indicate a significant improvement in profitability across both segments. The rise in adjusted gross margins illustrates effective absorption of fixed costs through increased volumes and operational efficiencies.
The adjusted gross margin totaled €91.1 million (48.8% of revenue) for H1 2024, a notable increase from €56.6 million in H1 2023 (45.3% of revenue). Breaking it down by segment, the adjusted gross margin for the Amplification segment grew to €65.2 million, while Detection & Imaging reached €25.8 million.
Strong Cash Flow Generation and Commitment to R&D
Exosens generated an impressive free cash flow of €23.6 million, a significant rise from €1.8 million in H1 2023. This robust cash flow is attributed to disciplined management of capital expenditures and a substantial contribution from organic growth.
Investment in R&D remains a top priority, with expenses amounting to €14.7 million (7.9% of sales) in H1 2024. This investment reflects strategic initiatives in innovative projects and recent acquisitions, highlighting Exosens's dedication to remaining at the forefront of technological advancements.
Strategic Capital Structure and 2024 Guidance
Following the successful IPO, Exosens has strengthened its capital structure, resulting in a notable reduction in net debt. The company maintains a strong outlook for 2024, expecting organic revenue growth in the high teens and adjusted EBITDA of at least €115 million. Additionally, net leverage is projected to be around 1.6x by year-end, following recent acquisitions.
Recent Developments and Acquisitions
After H1 2024, Exosens has further enhanced its growth trajectory through the acquisition of Centronics, which strengthens its position in radiation detection. Additionally, the acquisition of LR Tech, which specializes in environmental monitoring and gas detection, complements Exosens's offerings in cooled infrared technology.
Frequently Asked Questions
What are Exosens's key financial highlights for H1 2024?
Exosens reported a 50% revenue growth to €186.9 million, with an adjusted EBITDA of €56.1 million, indicating strong profitability.
How did Exosens achieve its growth?
The growth was driven by organic increases, successful acquisitions, and strategic collaborations within its sales and R&D teams.
What are Exosens's future expectations?
The company aims for high-teens organic revenue growth and an adjusted EBITDA of at least €115 million for FY 2024.
What strategies are in place for R&D investment?
Exosens is focusing on innovative projects while managing capital expenditure efficiently to optimize return on investment.
How has Exosens strengthened its financial position post-IPO?
The company has reduced net leverage to 1.3x while significantly increasing equity through a capital raise from the IPO.
